Telix Pharmaceuticals Limited (TLX)

Telix Pharmaceuticals was planning to go public, but the IPO was withdrawn on Jun 14, 2024.

IPO Price

$11.87

Shares Offered

17,000,000

Deal Size

$201.79M

Telix Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022
Market Capitalization	4,048	-	-
Enterprise Value	3,979	-	-
Debt / Equity Ratio	0.11	0.12	0.13
Debt / EBITDA Ratio	-	1.10	-0.11
Debt / FCF Ratio	1.76	1.33	-0.13
Quick Ratio	-	1.19	1.82
Interest Coverage	-	1.24	-13.74
Return on Equity (ROE)	17.48%	3.50%	-130.09%
Return on Assets (ROA)	-	1.31%	-40.76%
Return on Capital (ROIC)	24.94%	16.07%	-101.63%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).